The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective review on the interpretability and clinical application of the Centiloid (CL) ...

– GE HealthCare announced today that its MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a groundbreaking tool in the fight against Alzheimer’s disease.

Please provide your email address to receive an email when new articles are posted on . The FDA has granted 510(k) clearance to a Centiloid scaling apparatus software for positron emission ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A new predictive tool combining amyloid PET data with key clinical factors estimates an individual’s lifetime risk for mild cognitive impairment (MCI) and dementia years before symptoms, potentially ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density of amyloid plaque in the brains of people with Alzheimer’s disease. The ...

Amyloid imaging has transformed the diagnosis and monitoring of neurodegenerative diseases by enabling the in vivo detection of β-amyloid deposits, a pathological hallmark of Alzheimer’s disease and ...

In amyloid immunotherapy trials to date, biomarker change correlates with clinical efficacy, but the relationship is far from perfect. Plaque can fall and fluid biomarkers normalize without a ...

A large USC-led study suggests the main genetic risk factor for Alzheimer’s disease may be linked differently to brain amyloid buildup in Hispanic and non-Hispanic white older adults, underscoring the ...